Short Interest in NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) Drops By 16.2%

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) was the target of a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 51,900 shares, a decrease of 16.2% from the March 31st total of 61,900 shares. Based on an average daily trading volume, of 1,290,000 shares, the short-interest ratio is presently 0.0 days. Approximately 2.6% of the shares of the company are short sold.

NeuroBo Pharmaceuticals Trading Up 2.2 %

Shares of NeuroBo Pharmaceuticals stock traded up $0.07 during trading on Tuesday, reaching $3.30. The company’s stock had a trading volume of 42,189 shares, compared to its average volume of 1,015,278. NeuroBo Pharmaceuticals has a one year low of $2.89 and a one year high of $6.75. The business’s fifty day moving average price is $4.35 and its 200-day moving average price is $3.96.

NeuroBo Pharmaceuticals Company Profile

NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.